feed,title,long_url,short_url
Benzinga,FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?,https://benzinga.com/general/biotech/21/07/22013152/fibrogen-staring-at-multi-year-lows-following-adverse-roxadustat-adcom-verdict-how-hard-will-the-,https://j.mp/3wKn8G0
Benzinga,Calyxt Appoints Michael A. Carr As CEO,https://benzinga.com/news/21/07/22014114/calyxt-appoints-michael-a-carr-as-ceo,https://j.mp/3hIVvsC
